PetIQ (PETQ) Set to Announce Quarterly Earnings on Wednesday

PetIQ (NASDAQ:PETQ) will be announcing its earnings results after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of $0.41 per share for the quarter. PetIQ has set its FY 2024 guidance at EPS and its Q2 2024 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

PetIQ (NASDAQ:PETQ) last posted its quarterly earnings data on Wednesday, May 8th. The company reported $0.51 EPS for the quarter, topping the consensus estimate of $0.34 by $0.17. PetIQ had a net margin of 0.66% and a return on equity of 13.33%. The business had revenue of $308.44 million for the quarter, compared to analyst estimates of $302.16 million. On average, analysts expect PetIQ to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

PetIQ Price Performance

Shares of NASDAQ PETQ opened at $20.70 on Tuesday. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.25 and a current ratio of 2.42. The company has a 50 day simple moving average of $21.73 and a two-hundred day simple moving average of $19.16. PetIQ has a fifty-two week low of $15.09 and a fifty-two week high of $22.98. The company has a market capitalization of $615.87 million, a price-to-earnings ratio of 94.09 and a beta of 1.71.

Insider Activity at PetIQ

In other PetIQ news, Director Scott Huff sold 12,117 shares of the stock in a transaction on Wednesday, June 12th. The stock was sold at an average price of $22.19, for a total transaction of $268,876.23. The sale was disclosed in a filing with the SEC, which is available through this link. 9.62% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Separately, Benchmark reissued a “buy” rating and issued a $30.00 target price on shares of PetIQ in a report on Friday, May 10th. Four research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $29.00.

About PetIQ

PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.